BioSpace News Archive

Genetown

Blueprint Medicines Corp. Announces Proposed Public Offering of Shares of Common Stock

Blueprint Medicines today announced that it has commenced an underwritten public offering of $275,000,000 in shares of its common stock.

December 11, 2017

·

5 min read

Drug Development

Xenikos Announces Data From Phase I/II Trial With T-Guard for Treatment of Steroid-Resistant Acute GVHD Presented at ASH Annual Meeting

Treatment with a short course of T-Guard was generally well tolerated with no significant infusion reactions.

December 11, 2017

·

6 min read

Business

Varian Medical Announces First Quarter Fiscal Year 2018 Earnings Release Date

Varian today announced that it will report results for the first quarter of fiscal year 2018 after market close on Wednesday, January 24, 2018.

December 11, 2017

·

1 min read

Biotech Beach

Viking Therapeutics Announces Closing of Public Offering of Common Stock

The gross proceeds to Viking from this offering are approximately $14.8M, before deducting underwriting discounts and commissions and other estimated offering expenses.

December 11, 2017

·

4 min read

Biotech Bay

Revance Announces Closing of 6,139,515 Shares of Public Offering of Common Stock

Revance announced the closing of an underwritten public offering of 6,139,515 shares of its common stock at a price to the public of $31.00 per share.

December 11, 2017

·

3 min read

Drug Development

Verastem Announces the Presentation of Phase 1 Duvelisib Combination Data in T-Cell Lymphomas at the ASH 2017 Annual Meeting

There was a case of Stevens-Johnson syndrome resulting in death which was assessed by the investigator as possibly related to bortezomib, duvelisib, and trimethoprim-sulfamethoxazole, a medication that was initiated at the start of the study.

December 11, 2017

·

11 min read

Drug Development

Impact Biomedicines Presents Analysis at the 2017 ASH Annual Meeting Suggesting that Fedratinib Did Not Increase Wernicke Encephalopathy Risk in Phase II and III Myelofibrosis Clinical Trials

The results of these trials have been published in leading peer-reviewed journals.

December 11, 2017

·

4 min read

Business

Cloaked Therapeutics Development, LLC

Cloaked Therapeutics and Romulus Titan have formed a joint venture, Cloaked Therapeutics Development, LLC, to facilitate development of the TumorSelect cancer chemotherapy platform.

December 11, 2017

·

1 min read

Drug Development

Preclinical Data Supporting Wave Life Sciences ALS and FTD Programs Presented at 28th International Symposium on ALS/MND

Lead candidate targets C9ORF72; in vivo animal data demonstrate potent, sustained and preferential knockdown of toxic biomarkers associated with ALS and FTD.

December 11, 2017

·

7 min read

Drug Development

Targovax Announces That First Combination Trials With ONCOS-102 Have Passed Their Initial, Planned, Independent Safety Reviews

These are the first studies to investigate ONCOS-102 in combination with other drugs.

December 11, 2017

·

4 min read